US20130197612A1 - Electromagnetic Radiation Therapy - Google Patents

Electromagnetic Radiation Therapy Download PDF

Info

Publication number
US20130197612A1
US20130197612A1 US13/023,110 US201113023110A US2013197612A1 US 20130197612 A1 US20130197612 A1 US 20130197612A1 US 201113023110 A US201113023110 A US 201113023110A US 2013197612 A1 US2013197612 A1 US 2013197612A1
Authority
US
United States
Prior art keywords
electromagnetic radiation
energy
kidney
injury
applicator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/023,110
Other languages
English (en)
Inventor
Jack W. Lasersohn
Michael J. Horzewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/023,110 priority Critical patent/US20130197612A1/en
Publication of US20130197612A1 publication Critical patent/US20130197612A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18471—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Definitions

  • This invention relates to the use of electromagnetic radiation for the prevention and treatment of injury to and disorders of biological issues, and more specifically to novel apparatuses and methods for the prevention and treatment of kidney injury and failure.
  • Acute renal failure or acute kidney injury is characterized by a rapid reduction in renal function.
  • the causes are numerous and are commonly categorized as pre-renal, renal or intrinsic, and post-renal.
  • Pre-renal causes are characterized by inadequate blood perfusion to the kidneys. These include volume depletion; examples include hemorrhage, loss of intravascular fluid due to ascities, peritonitis, and burns; low cardiac output due to cardiomyopathy, myocardial infarction, cardiac tamponade, and pulmonary embolism, among others; low systemic vascular resistance due to shock, liver failure, or antihypertensive drugs; increased vascular resistance caused by hypercalcemia, anaphylaxis, anesthetics, renal artery obstruction, renal vein thrombosis, sepsis, and hepatorenal syndrome; and decreased efferent arteriolar tone.
  • Renal causes involve intrinsic renal disease or damage to the kidney itself, most commonly from renal ischemia and nephrotoxins.
  • Causes include acute tubular injury due to ischemia; from surgery (blood loss, blood flow reduction-cross clamping), hemorrhage, arterial or venous obstruction, and cyclosporine, tacrolimus, and amphotericin B; and toxins, such as radiopaque contrast agents which lead to contrast-induced nephropathy, Aminoglycosides, amphotericin B, foscarnet, ethylene glycol, hemoglobinuria, myoglobinuria, ifosfamide, and heavy metals.
  • Acute glomerulonephritis ANCA associated, anti-GBM glomerulonephritis, and immune complex
  • acute tubulointerstitial nephritis due to drug reactions, pyelonephritis, and papillary necrosis
  • acute vascular nephropathy from vasculitis malignant hypertension
  • thrombotic microangiopathies scleroderma
  • atheroembolism and infiltrative diseases
  • lymphoma, sarcoidosis, and leukemia constitute renal causes as well.
  • Post-renal causes are due to various types of obstruction within the urinary system. Obstruction can also occur within the tubules when crystalline or proteinaceous material precipitates. Examples include: renal calculi; retroperitoneal fibrosis; prostatic hypertrophy; carcinoma and cervical carcinoma; urethral stricture; and bladder, pelvic, and/or retroperitoneal neoplasm.
  • the primary treatment for acute kidney injury is correcting the fluid and electrolyte balances from either fluid depletion or fluid overload; treatment of the underlying medical condition and restoration of blood perfusion to the kidneys; and the discontinuation of potentially deleterious medications.
  • Non-ICU acute kidney injury carries a mortality rate of up to 10%.
  • ICU acute kidney injury carries a mortality rate of over 50%.
  • Contrast-induced nephropathy is associated with both short- and long-term adverse outcomes, including the need for renal replacement therapy, increased length of hospital stay, major cardiac adverse events, and mortality.
  • the incidence of contrast-induced nephropathy is estimated to be 1% to 6% in the general population. However, in patient subgroups with multiple comorbidities, the risk grows to as high as 50%.
  • pharmacologic interventions have been evaluated for the prevention of contrast-induced nephropathy, including: angiotensin II, fenoldopam, dopamine, calcium-channel blockers, endothelin antagonists, and adenosine, though none of these have been found to be beneficial.
  • the principal intervention is extracellular volume expansion, primarily with the administration of intravenous fluid.
  • Other pharmacologic agents, N-acetylcysteine, sodium bicarbonate, and ascorbic acid have seen mixed results in clinical trials are still under evaluation to determine if they provide a beneficial effect.
  • Electromagnetic radiation systems of many different types are used in a wide variety of medical procedures. Some of the many types of electromagnetic radiation systems are visible light systems and infrared systems; some are intended for diagnostic purposes, such as infrared spectroscopy, and some for therapeutic purposes including chronic pain management, wound healing, cosmetic surgery, and dentistry.
  • Electromagnetic radiation in the red/near infrared range has been shown to modulate various biological processes such as increasing mitochondrial respiration, adenosine triphosphate synthesis, and preventing apoptosis. This effect has been applied clinically to facilitate wound healing; promote skeletal muscle regeneration and angiogenesis; and improve neurologic function in ischemic brain tissue.
  • the mechanism of action in these uses is not well understood.
  • the problem of nephropathy caused by contrast agents is distinct from these prior uses and is itself not well understood.
  • One preferred embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, to prevent, reduce, or eliminate injury to the kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue prior to kidney injury, to prevent, reduce, or eliminate injury to the kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue at least during a portion of the time of kidney injury, to prevent, reduce, or eliminate injury to the kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, at least during a portion of the time of and/or after the kidney injury, to prevent, reduce, or eliminate injury to the kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of and/or after the kidney injury, to prevent, reduce, or eliminate injury to the kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of a diagnostic procedure, to prevent, reduce, or eliminate injury to the kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of an interventional procedure, to prevent, reduce, or eliminate injury to the kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, concurrently or independently applying acoustic energy of at least one efficacious energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of and/or after the kidney injury, to prevent, reduce, or eliminate injury to the kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, concurrently or independently applying acoustic energy of at least one efficacious energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of and/or after the kidney injury, to prevent, reduce, or eliminate contrast-induced nephropathy.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, concurrently or independently applying acoustic energy of at least one efficacious energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of and/or after the introduction of contrast media to the patient, to prevent, reduce, or eliminate contrast-induced nephropathy.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, concurrently or independently applying a magnetic field of at least one efficacious field strength to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of and/or after the kidney injury, to prevent, reduce, or eliminate injury to the kidney tissue.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises ‘introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of and/or after the kidney injury, and administering a pharmacologic agent (e.g. hydration, volume expansion, N-acetylcysteine, sodium bicarbonate, ascorbic acid) prior to and/or at least during a portion of the time of and/or after electromagnetic radiation, to prevent, reduce, or eliminate injury to the kidney tissue.
  • a pharmacologic agent e.g. hydration, volume expansion, N-acetylcysteine, sodium bicarbonate, ascorbic acid
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of an interventional procedure, and administering a pharmacologic agent (e.g. hydration, volume expansion, N-acetylcysteine, sodium bicarbonate, ascorbic acid) prior to and/or at least during a portion of the time of and/or after electromagnetic radiation, to prevent, reduce, or eliminate injury to the kidney tissue.
  • a pharmacologic agent e.g. hydration, volume expansion, N-acetylcysteine, sodium bicarbonate, ascorbic acid
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue.
  • the electromagnetic radiation source comprising a laser and/or at least one light emitting diode.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue. Introducing the electromagnetic radiation through an element in contact with the skin.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue. Reducing thermal changes near the skin.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue. Sensing for thermal changes and modifying or ceasing delivery of the electromagnetic radiation if predetermined thermal changes are detected.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue. Sensing for electromagnetic radiation of at least one efficacious wavelength and ceasing delivery of the electromagnetic radiation if electromagnetic radiation of at least one efficacious wavelength is detected.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue. Sensing for electromagnetic radiation of at least one efficacious wavelength and ceasing delivery of the electromagnetic radiation if electromagnetic radiation of at least one efficacious wavelength is detected above a threshold level.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, to prevent, reduce, or eliminate injury to the kidney tissue. Concurrently or independently of the delivery of electromagnetic radiation effecting a decrease in the absorption and/or blood flow and/or blood vessel diameter in at lease a portion of the area exposed to the electromagnetic radiation.
  • Another embodiment of the present invention provides a method for treating kidney tissue.
  • the method comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, to prevent, reduce, or eliminate injury to the kidney tissue. Concurrently or independently of the delivery of electromagnetic radiation effecting an increase in the transmission of the electromagnetic radiation.
  • the methods encompass using electromagnetic radiation having at least one wavelength of about 635 nm to about 1560 nm.
  • the methods encompass using electromagnetic radiation having at least one wavelength of about 635 nm to about 980 nm.
  • the methods encompass using electromagnetic radiation having at least one wavelength of about 700 nm to about 980 nm.
  • the methods encompass using electromagnetic radiation having a power density of at least 0.01 mW/cm 2 at the kidney tissue.
  • the methods encompass using electromagnetic radiation having an energy density of at least 0.01 J/cm 2 at the kidney tissue.
  • the methods encompass delivering electromagnetic radiation in at least continuous wave mode.
  • the methods encompass delivering electromagnetic radiation in at least pulsed wave mode.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprising a laser and/or at least one light emitting diode as one electromagnetic radiation source.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises an element in contact with the skin.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises an element in contact with the skin. The element adapted to reduce thermal changes near the skin.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises and element in contact with the skin. The element adapted to reduce the temperature near the skin at or near the region of irradiation.
  • Another embodiment of the present invention provides an apparatus for treating kidney tissue.
  • the apparatus comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue.
  • the apparatus further comprises a sensor for sensing thermal changes and modifying or ceasing delivery of the electromagnetic radiation if predetermined thermal changes are detected.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises an element to reduce or eliminate electromagnetic radiation of at least one efficacious wavelength from being emitted in at least one undesirable direction.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises an element to reduce or eliminate electromagnetic radiation of at least one efficacious wavelength from being emitted away from the patient.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises an element for constraining the electromagnetic radiation of at least one efficacious wavelength being emitted between the emitting source and the patient.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises an element for maintaining position of at least on element of the apparatus in relation to the patient.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises a sensor to sense electromagnetic radiation of at least one efficacious wavelength.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises a sensor to sense electromagnetic radiation of at least one efficacious wavelength.
  • the apparatus further comprises an element or component for ceasing delivery of the electromagnetic radiation if electromagnetic radiation of at least one efficacious wavelength is detected.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further comprises a sensor to sense electromagnetic radiation of at least one efficacious wavelength.
  • the apparatus further comprises an element or component for ceasing delivery of the electromagnetic radiation if electromagnetic radiation of at least one efficacious wavelength is detected above a threshold level.
  • Another embodiment of the present invention provides an apparatus for treating kidney tissue.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy and at least one acoustic energy source of at least one efficacious energy.
  • the apparatus further comprising the delivery of the efficacious energies either concurrently or independently to at least a portion of kidney tissue.
  • Another embodiment of the present invention provides an apparatus for treating kidney tissue.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy and at least one magnetic field source of at least one efficacious field strength.
  • the apparatus further comprising the delivery of the efficacious energies either concurrently or independently to at least a portion of kidney tissue.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further affecting, concurrently or independently of the delivery of electromagnetic radiation, a decrease in the absorption and/or blood flow and/or blood vessel diameter in at least a portion of the area exposed to the electromagnetic radiation.
  • the apparatus comprises at least one electromagnetic radiation source of at least one efficacious wavelength and energy, positioned to irradiate at least a portion of kidney tissue.
  • the apparatus further affecting, concurrently or independently of the delivery of electromagnetic radiation, an increase in the transmission of the electromagnetic radiation.
  • the apparatus encompasses using electromagnetic radiation having at least one wavelength of about 635 nm to about 1560 nm.
  • the apparatus encompasses using electromagnetic radiation having at least one wavelength of about 635 nm to about 980 nm.
  • the apparatus encompasses using electromagnetic radiation having at least one wavelength of about 700 nm to about 980 nm.
  • the apparatus encompasses using electromagnetic radiation having a power density of a power density of at least 0.01 mW/cm 2 at the kidney tissue.
  • the apparatus encompasses using electromagnetic radiation in at least continuous wave mode.
  • the apparatus encompasses using electromagnetic radiation in at least pulsed wave mode.
  • FIG. 1 illustrates a system 10 for applying electromagnetic radiation energy for the prevention, reduction, or elimination of acute kidney injury and/or kidney failure.
  • FIG. 2 illustrates an embodiment of the system 10 with multiple applicators 30 .
  • FIG. 3 illustrates a view of the patient side of an applicator 30 .
  • FIG. 4 illustrates an embodiment of the system 10 with a cooling system 90 .
  • FIG. 6 illustrates an embodiment of a multiple source system 200 .
  • the electromagnetic radiation energy is desirably indicated, e.g., for the prevention, reduction, or elimination of acute kidney injury and/or kidney failure; and/or before, during, or after the acute kidney injury and/or kidney failure has begun; and/or before, during, or after a new kidney injury and/or insult has occurred, e.g. angiographic procedures, surgical procedures, contrast-enhanced imaging procedures, any introduction of contrast media to a patient, etc.
  • injury or “insult” as they relate to the kidneys shall mean any tissue injury, insult, or damage resulting from any or all of the following causes: pre-renal, renal or intrinsic, and post-renal.
  • FIG. 1 schematically shows a compact, portable electromagnetic energy system 10 that makes it possible to apply electromagnetic energy to a patient.
  • the system 10 enables the application of electromagnetic radiation energy to a patient at a designated treatment location.
  • the system 10 will be described herein for irradiation of the kidneys for the prevention, reduction, or elimination of acute kidney injury and/or kidney failure, understanding it is within the scope of the present invention that the system 10 may be modified for irradiation of other tissues within the body.
  • the source 20 may be, for example at least one light emitting diode, laser, and/or laser diode, or multiples and/or a combination of sources, e.g. laser and light emitting diodes.
  • Power for the machine 15 may be supplied from an internal battery (rechargeable and/or removable, if so desired), external battery, and/or line source.
  • the provision of battery power frees the machine 15 from dependency upon electrical service. This feature makes it possible for the machine 15 to operate in multiple locations and while the patient is being transported between locations, e.g. from the holding area to the catheterization laboratory, from the catheterization laboratory to the holding area or hospital room, etc.
  • the applicator 30 is sized to irradiate at least both kidneys, taking into account the size and location of the kidneys, as well as the divergence of the electromagnetic energy within the tissue. For example, given the average kidney size of about 11 cm in height, by 6 cm in width, by 5 cm thick, at a depth of 7.5 cm, with a separation of 11 cm, a location asymmetry of 1 cm (the right kidney generally being lower than the left), and divergence of the electromagnetic radiation within the tissue of 15 degrees, an average applicator 30 would be about 20 cm by 9 cm. Applicators of varying sizes may be provided based on the patient's characteristics and/or the desired area of irradiation. The desired area of irradiation may be greater, equal to, or less than the size of the target tissue.
  • the securement of the applicator 30 may be designed to apply pressure to the patient's skin in the region of the applicator 30 .
  • Securement of applicator 30 by the seal 60 , band, or other methods may serve as to direct the electromagnetic radiation energy to the patient and/or from eliminating any electromagnetic radiation of emanating into the surrounding area or environment.
  • Additional methods and apparatuses to decrease the absorption and/or amount of blood and/or the blood vessel diameter in at least a portion of the area of electromagnetic irradiation is to decrease the temperature in at least a portion of the area. For example, this can be effected by cooling at least a portion of the applicator 30 , or by use of an independent cooling apparatus, prior to and/or concurrently with the delivery of electromagnetic radiation.
  • Additional methods and apparatuses to decrease the absorption and/or amount of blood and/or the blood vessel diameter in at least a portion of the area of electromagnetic irradiation are to apply an energy source to at least a portion of the area. For example, this can be effected by applying a vasoconstrictive energy, e.g. electrical stimulation, to at least a portion of the area prior to and/or concurrently with the delivery of electromagnetic radiation.
  • a vasoconstrictive energy e.g. electrical stimulation
  • Additional methods of providing pressure are to fill at least a portion of the applicator 30 or space between the applicator 30 and patient with a fluid.
  • This fluid could be used, for example, thermal maintenance or cooling, to enhance transmission of the electromagnetic energy, etc.
  • the region 70 not covered by the seal 60 may contain a transmission gel (not shown) to both enhance electromagnetic radiation transmission and apply pressure to the patient in the region of the applicator 30 .
  • the transmission gel may be cooled and/or contain a vasoconstrictive agent.
  • the applicator 30 may be constructed of materials such that the applicator 30 is partially or wholly translucent or transparent under fluoroscopy, as to not completely inhibit visualization in the catheterization laboratory.
  • the interconnect 40 couples the machine 15 to the applicator 30 .
  • the interconnect 40 may be a separate component or it may be part of the machine 15 and/or part of the applicator 30 .
  • the interconnect 40 enables the transmission of electromagnetic radiation from the machine 15 to the applicator 30 .
  • the interconnect 40 may also include electrical and optical components, as will be described herein.
  • the interconnect 40 may be sized to enable the applicator 30 to remain within a sterile field while the machine 15 is outside the sterile field, when used in sterile settings.
  • a controller 50 may have one or more functions. These functions may include but are not limited to, power on/off control, set and/or track the time of electromagnetic radiation delivery, initiate and/or cease electromagnetic radiation delivery, change the energy of the source 20 based on the applicator connected to it, control operation of multiple sources 20 (e.g. laser and light emitting diode sources), monitor and/or control thermal and/or cooling components and/or modify source 20 output parameters and/or energy delivery based on feedback from one or more sensors (e.g. thermal and/or optical sensors), and control continuous and/or pulsed mode operation.
  • a controller 50 or other component may also recognize the status of the system 10 connections (e.g.
  • a controller 50 or other component may also recognize the type and/or status of the applicator 30 and only allow electromagnetic energy delivery when the proper applicator 30 is connected.
  • Thermal sensing at or near the patient interface may be desirable. Additionally, thermal control of and/or near the applicator 30 and/or patient interface may also be desirable.
  • the thermal control may, for example, be a sensor to monitor the temperature at and/or near the applicator 30 , and/or whereby a controller 50 adjusts the power output of the source 20 , operates an active cooling system ( FIG. 4 ), changes output mode (to/from continuous to/from pulsed to/from cycled off and on in either mode), ceases power output.
  • Thermal control may be passive, for example, a fluid filled applicator 30 being filled with and/or incorporating a cold liquid, solid, or gel.
  • the decreased temperature may be from cold storage of the component, through a chemical reaction, or other mechanism.
  • the thermal control may be active, e.g. circulating cold fluid through at least a portion of the applicator 30 or the region of the patient interface.
  • a sensor may be used as feedback to control the cooling system to maintain certain parameters, e.g. a specific temperature or a temperature range.
  • a detection system is an electromagnetic radiation sensor 66 shown in FIG. 1 , which detects the delivered wavelength(s) should the system 10 irradiate an undesirable area, e.g. towards persons other than the patient, into the catheterization laboratory, surgical suite, environment, etc.
  • the minimum threshold energy of the delivered electromagnetic radiation wavelength(s) is exceeded, the system 10 conducts an additional operation.
  • Minimum threshold energy level may be determine by sensing ambient energy levels prior to the delivery of electromagnetic radiation, and having the threshold level set at a value greater than ambient, e.g. 10% above ambient.
  • sensor or sensors may be varied as well as the operation or operations conducted by the sensor, and/or controller 50 , and/or system 10 .
  • Multiple sources 20 may generate electromagnetic radiation energy at the same or different wavelengths and the same or different energy levels, e.g. light emitting diode(s) operating at 635 nm and a laser operating at 808 nm with similar of different energy levels. Irradiation of the tissue from each source 20 may occur at separate time points and/or at the same time and/or combinations thereof. Operating modes for the delivery of electromagnetic radiation energy may be continuous wave, pulsed wave, and/or a combination within each source and between sources.
  • the efficacious power density at the target tissue be at least 0.01 mW/cm 2 . More preferably the power density at the target tissue is 1 mW/cm 2 to 300 mW/cm 2 . Most preferably the power density at the target tissue is 1 mW/cm 2 to 50 mW/cm 2 in continuous mode and in pulsed mode the peak power density is 5 mW/cm 2 to 250 mW/cm 2 .
  • pulsed mode electromagnetic radiation at higher power densities at the skin surface enables higher peak power densities to be achieved at the kidney tissue and/or potentially expands the range of useful wavelengths able to deliver efficacious energy to the kidney tissue.
  • the source 20 would need to provide 39 W of power output from the applicator 20 .
  • the power density was measured at the opposite side of the kidney from the applicator.
  • the efficacious power density range applies to power densities delivered to the surface of the kidney and/or within the kidney and/or at the opposite side of the kidney from the applicator.
  • the efficacious wavelength and power density ranges are suitable to prevent, decrease, or eliminate tissue injury or damage resulting from, for example, ischemia and/or an ischemic event and/or external and/or intrinsic toxicity.
  • these efficacious wavelength and power density ranges are suitable to prevent, decrease, or eliminate tissue injury or damage resulting from pre-renal, renal or intrinsic, and post-renal causes.
  • An alternative embodiment is to introduce electromagnetic radiation to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of and/or after the kidney injury, and administering a pharmacologic agent (e.g. hydration, volume expansion, N-acetylcysteine, sodium bicarbonate, ascorbic acid) prior to and/or at least during a portion of the time of and/or after electromagnetic radiation, to prevent, reduce, or eliminate injury to the kidney tissue.
  • a pharmacologic agent e.g. hydration, volume expansion, N-acetylcysteine, sodium bicarbonate, ascorbic acid
  • An alternative embodiment is to introduce electromagnetic radiation to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of and/or after an interventional procedure, and administering a pharmacologic agent (e.g. hydration, volume expansion, N-acetylcysteine, sodium bicarbonate, ascorbic acid) prior to and/or at least during a portion of the time of and/or after electromagnetic radiation, to prevent, reduce, or eliminate injury to the kidney tissue.
  • a pharmacologic agent e.g. hydration, volume expansion, N-acetylcysteine, sodium bicarbonate, ascorbic acid
  • An alternative embodiment is to provide a combination system 100 with the electromagnetic radiation energy source near and/or adjacent to, and/or being part of the applicator.
  • This combination source/applicator 130 as shown in FIG. 5 is for example, a light emitting diode array as part of the applicator.
  • Combination system 100 may contain and/or a combination controller 150 , source/power supply 117 (internal or external), source/power interconnect 140 . All features described as part of the present invention are applicable to a combination system 100 .
  • An alternative embodiment is to provide a multiple source system 200 with two sources, e.g. a laser and a light emitting diode array as shown in FIG. 6 .
  • the multiple source system 200 may comprise an applicator containing or near or adjacent to at least one electromagnetic radiation energy source and/or at least one source not at, near, or adjacent the applicator.
  • This multiple source/applicator 230 is for example, a light emitting diode array 226 as part of the applicator and a laser source 220 with an output window 225 located at, near, or adjacent the patient.
  • the multiple source/applicator 230 would provide for irradiation of the patient by both sources, from the light emitting diode array 226 and from the laser source through the output window 225 .
  • Multiple source system 200 may contain and/or at least one multiple source controller 250 , multiple source power supply 217 , power/electromagnetic radiation interconnect 240 . All features described as part of the present invention are applicable to a multiple source system 200
  • Electromagnetic radiation energy may be used with other energy delivery sources at separate time points and/or at the same time and/or combinations thereof. Examples of such sources are, but not limited to, acoustic energy (including ultrasound) and magnetic energy, and electrical energy. Application of multiple energies may provide an enhanced effect compared to electromagnetic energy alone.
  • Angiography A patient requires an angiogram. Prior to the angiogram, the patient is determined to be at high risk for kidney injury due to the use of contrast media. It is determined to use system 10 to prevent, reduce, or eliminate kidney injury.
  • Transmission gel is cooled and applied to the region 70 of the applicator 30 .
  • Applicator 30 is secured to patient's back using seal 60 , in the region of the kidneys (generally located between T12 to L3).
  • the applicator 30 is connected to interconnect 40 and machine 15 .
  • the patient lies on their back on the catheterization laboratory table and by design of the applicator 30 , pressure is applied to the patient's skin in the area covered the applicator 30 .
  • Continuous mode transmission of electromagnetic energy from laser source 20 at 808 nm and a power density of 2 mW/cm 2 at the far side of the kidneys is initiated 15 minutes prior to first contrast injection and is delivered for a duration of 10 minutes.
  • Angiography 2 A patient requires an angiogram. Prior to the angiogram, the patient is determined to be at high risk for kidney injury due to the use of contrast media. It is determined to use system 10 to prevent, reduce, or eliminate kidney injury.
  • the patient receives and angiogram.
  • a vasoconstrictive agent is applied to the patient contact surface of the source/applicator 230 .
  • Transmission gel is cooled and applied to the region 70 of the applicator 30 .
  • Applicator 30 is secured to patient's back using seal 60 , in the region of the kidneys (generally located between T12 to L3) and by design of the applicator 30 , pressure is applied to the patient's skin in the area covered the applicator 30 .
  • the applicator 30 is connected to interconnect 40 and machine 15 . Pulsed mode transmission of electromagnetic energy from laser source 20 at 635 nm and a power density of 10 mW/cm 2 at the surface of the kidneys is delivered for a duration of 2 minutes.
  • Additional irradiations may occur at various intervals. These include but are not limited to once only or one or more times per day for one or more days or one or more times per day with a day or days without irradiation interspersed between irradiation days, e.g. skip days.
  • Percutaneous transluminal coronary angioplasty A patient requires percutaneous transluminal coronary angioplasty (PTCA). Prior to the PTCA, the patient is determined to be at high risk for kidney injury due to the use of contrast media. It is determined to use system 10 to prevent, reduce, or eliminate kidney injury.
  • PTCA percutaneous transluminal coronary angioplasty
  • Transmission gel is applied to the region 70 of the applicator 30 .
  • Applicator 30 is secured to patient's back using seal 60 , in the region of the kidneys.
  • the applicator 30 is connected to interconnect 40 and machine 15 and machine 15 is plugged into wall power.
  • the patient lies on their back and by design of the applicator 30 , pressure is applied to the patient's skin in the area covered the applicator 30 .
  • Continuous mode transmission of electromagnetic energy from laser source 20 at 808 nm and a power density of 10 mW/cm 2 at the surface of the kidneys is delivered for 2 minutes duration, initiated 30 minutes prior to first contrast injection.
  • Seal sensor 65 continuously monitors for 808 nm electromagnetic radiation, does not detect any, and continues delivery of energy.
  • Continuous wave electromagnetic radiation energy is delivered again at 6 hours post procedure and twice per day with a 6 hour separation between irradiations for one or more days following the procedure.
  • System 10 operates on battery power while patient is moved between areas, where the machine 15 may be plugged back into wall power.
  • the controller 50 if operating in continuous mode, may switch to pulsed mode and deliver pulsed mode electromagnetic radiation energy, e.g. if there is an increase in temperature. Based on the patient's status, delivery of electromagnetic radiation energy may be cycled on and off by the controller 50 .
  • Coronary artery bypass graft surgery A patient requires a coronary artery bypass graft surgery. It is determined to use combination system 200 , incorporating cooling system 90 , to prevent, reduce, or eliminate kidney injury.
  • Transmission gel is applied to the region 70 of the multiple source/applicator 230 .
  • Multiple source/applicator 230 is secured to patient's back using seal 60 , in the region of the kidneys (T12 to L3).
  • the multiple source/applicator 230 is connected to the power/electromagnetic radiation interconnect 240 and multiple source power supply 217 .
  • Disposable membrane of multiple source/applicator 230 is fluid filled to exert pressure on the patient's skin.
  • a transmission gel containing a vasoconstrictive agent is applied to the patient contact surface of the source/applicator 230 .
  • Continuous mode transmission of electromagnetic radiation energy from light emitting diode array 226 at 635 nm and 25 mW/cm 2 and pulsed mode electromagnetic radiation energy is delivered through output window 225 at 808 nm and a power density of 25 mW/cm 2 at the kidneys.
  • Two minutes of electromagnetic radiation is delivered 24 hours prior to the procedure, during which electromagnetic radiation sensor 66 continuously monitors for electromagnetic radiation in the 600 nm to 900 nm range, does not detect any amount above the threshold level, and allows delivery of energy.
  • System 10 operates on battery power in case the patient needs to be moved until the multiple source power supply 217 is plugged back into wall power.
  • the multiple source controller 250 may switch off the 808 nm source and continue delivery of the 635 nm electromagnetic radiation energy, now switched to pulsed mode. During irradiation, the cooling system 90 is cycled by the multiple source controller 250 to maintain a preset temperature and reduce blood flow in the area. Based on the patient's status, electromagnetic radiation energy may be delivered from either or both sources at a variety of power levels and modes of operation, or discontinued. Similarly, an additional 2 minutes of electromagnetic radiation is delivered to the patient during the procedure and every 24 hours post procedure for an additional three days.
  • Another preferred embodiment of the present invention is a method for preventing, reducing, or eliminating acute kidney injury and/or kidney failure by the application of electromagnetic radiation energy. At least a portion of one kidney is irradiated with electromagnetic radiation energy at an efficacious wavelength and power density and/or before, during, or after the acute kidney injury and/or kidney failure has begun; and/or before, during, or after a new kidney injury and/or insult has occurred.
  • a method for preventing, reducing, or eliminating acute kidney injury and/or kidney failure by the application of electromagnetic radiation energy is provided. At least a portion of one kidney is irradiated with electromagnetic radiation energy at an efficacious wavelength and power density and/or before, during, or after surgery.
  • a method for preventing, reducing, or eliminating acute kidney injury and/or kidney failure by the application of electromagnetic radiation energy is provided. At least a portion of one kidney is irradiated with electromagnetic radiation energy at an efficacious wavelength and power density and/or before, during, or after the introduction of contrast media to the patient.
  • a method for preventing, reducing, or eliminating contrast-induced nephropathy by the application of electromagnetic radiation energy is provided. At least a portion of one kidney is irradiated with electromagnetic radiation energy at an efficacious wavelength and power density and/or before, during, or after the introduction of contrast media to the patient.
  • a method for preventing, reducing, or eliminating contrast-induced nephropathy by the application of electromagnetic radiation energy is provided. At least a portion of one kidney is irradiated with electromagnetic radiation energy at an efficacious wavelength and power density and/or before, during, or after angiography.
  • a method for preventing, reducing, or eliminating contrast-induced nephropathy by the application of electromagnetic radiation energy is provided. At least a portion of one kidney is irradiated with electromagnetic radiation energy at an efficacious wavelength and power density and/or before, during, or after contrast-enhanced imaging.
  • a method for preventing, reducing, or eliminating acute kidney injury and/or kidney failure by the application of electromagnetic radiation energy Prior to the introduction of contrast media to the patient, the patient is identified as being at risk of experiencing acute kidney injury and/or kidney failure. Electromagnetic radiation energy at an efficacious wavelength and power density is delivered to at least a portion of the patient's kidney or kidneys before and/or during and/or after the introduction of contrast media to the patient.
  • a method for preventing, reducing, or eliminating acute kidney injury and/or kidney failure by the application of electromagnetic radiation energy Prior to a diagnostic and/or interventional procedure, the patient is identified as being at risk of experiencing acute kidney injury and/or kidney failure. Electromagnetic radiation energy at an efficacious wavelength and power density is delivered to at least a portion of the patient's kidney or kidneys before and/or during and/or after the diagnostic and/or interventional procedure.
  • a method for preventing, reducing, or eliminating acute kidney injury and/or kidney failure by the application of electromagnetic radiation energy Prior to surgery, the patient is identified as being at risk of experiencing acute kidney injury and/or kidney failure. Electromagnetic radiation energy at an efficacious wavelength and power density is delivered to at least a portion of the patient's kidney or kidneys before and/or during and/or after the surgery.
  • a method for preventing, reducing, or eliminating contrast-induced nephropathy by the application of electromagnetic radiation energy Prior to the introduction of contrast media to the patient, the patient is identified as being at risk of experiencing contrast-induced nephropathy.
  • Electromagnetic radiation energy at an efficacious wavelength and power density is delivered to at least a portion of the patient's kidney or kidneys before and/or during and/or after the introduction of contrast media to the patient.
  • a method for changing or maintaining the temperature of at least a portion of the patient's tissue prior to and/or during and/or after irradiating at least a portion of the patient's kidney with electromagnetic energy.
  • a method for changing the pressure on at least a portion of the patient's skin and/or tissue prior to and/or during and/or after irradiating at least a portion of the patient's kidney with electromagnetic energy.
  • a method for decreasing the absorption and/or amount of blood and/or the blood vessel diameter in at least a portion of the area of electromagnetic irradiation prior to and/or during and/or after irradiating at least a portion of the patient's kidney with electromagnetic energy.
  • a method for sensing at least one electromagnetic energy wavelength and performing an operation if that at least one wavelength is detected.
  • a method for preventing, reducing, or eliminating acute kidney injury and/or kidney failure by the application of electromagnetic radiation energy At least a portion of one kidney is irradiated with electromagnetic radiation energy at an efficacious wavelength and power density and at least one additional energy is delivered to at least a portion of one kidney and/or before, during, or after the acute kidney injury and/or kidney failure has begun; and/or before, during, or after a new kidney injury and/or insult has occurred.
  • a method for preventing, reducing, or eliminating acute kidney injury and/or kidney failure comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of and/or after the kidney injury, and administering a pharmacologic agent prior to and/or at least during a portion of the time of and/or after electromagnetic radiation, to prevent, reduce, or eliminate injury to the kidney tissue.
  • a method for preventing, reducing, or eliminating acute kidney injury and/or kidney failure comprises introducing electromagnetic radiation of at least one efficacious wavelength and energy to at least a portion of kidney tissue, prior to and/or at least during a portion of the time of an interventional procedure, and administering a pharmacologic agent prior to and/or at least during a portion of the time of and/or after electromagnetic radiation, to prevent, reduce, or eliminate injury to the kidney tissue.
US13/023,110 2010-02-26 2011-02-08 Electromagnetic Radiation Therapy Abandoned US20130197612A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/023,110 US20130197612A1 (en) 2010-02-26 2011-02-08 Electromagnetic Radiation Therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30862010P 2010-02-26 2010-02-26
US13/023,110 US20130197612A1 (en) 2010-02-26 2011-02-08 Electromagnetic Radiation Therapy

Publications (1)

Publication Number Publication Date
US20130197612A1 true US20130197612A1 (en) 2013-08-01

Family

ID=44022809

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/023,110 Abandoned US20130197612A1 (en) 2010-02-26 2011-02-08 Electromagnetic Radiation Therapy
US13/035,904 Active 2031-08-06 US9327137B2 (en) 2010-02-26 2011-02-25 Recombinant CDV compositions and uses thereof
US15/084,108 Active US10076566B2 (en) 2010-02-26 2016-03-29 Recombinant CDV compositions and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/035,904 Active 2031-08-06 US9327137B2 (en) 2010-02-26 2011-02-25 Recombinant CDV compositions and uses thereof
US15/084,108 Active US10076566B2 (en) 2010-02-26 2016-03-29 Recombinant CDV compositions and uses thereof

Country Status (23)

Country Link
US (3) US20130197612A1 (es)
EP (1) EP2538972B1 (es)
JP (1) JP5898632B2 (es)
KR (1) KR20130036209A (es)
CN (1) CN102971010A (es)
AR (1) AR080313A1 (es)
AU (1) AU2011220410B9 (es)
BR (1) BR112012021545B1 (es)
CA (1) CA2791787C (es)
CY (1) CY1120430T1 (es)
DK (1) DK2538972T3 (es)
ES (1) ES2676542T3 (es)
HR (1) HRP20181188T1 (es)
HU (1) HUE039735T2 (es)
LT (1) LT2538972T (es)
NZ (1) NZ602077A (es)
PL (1) PL2538972T3 (es)
PT (1) PT2538972T (es)
RS (1) RS57759B1 (es)
RU (1) RU2567337C2 (es)
SI (1) SI2538972T1 (es)
WO (1) WO2011106743A1 (es)
ZA (1) ZA201206209B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103525776A (zh) * 2013-10-23 2014-01-22 华中农业大学 一种重组狂犬病病毒口服疫苗株及其制备方法
CN104164409A (zh) * 2014-07-18 2014-11-26 中国人民解放军军事医学科学院军事兽医研究所 含有犬gmcsf基因的重组犬瘟热病毒及其制备方法
US10081796B2 (en) * 2015-01-12 2018-09-25 International Aids Vaccine Initiative Neutralization-resistant CDV mutants and viral vectors
CN109715204B (zh) 2016-09-20 2023-08-22 勃林格殷格翰动物保健有限公司 新的ehv插入位点orf70
TW201823467A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 犬腺病毒載體
AR109540A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Moléculas promotoras para expresar antígenos virales
EP3515480A1 (en) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH New swine influenza vaccine
CN109265522B (zh) * 2018-09-29 2022-03-04 东北农业大学 用于检测犬瘟热病毒血凝蛋白h抗体的致敏聚苯乙烯纳米微球及其制备方法和应用
WO2020086939A1 (en) * 2018-10-26 2020-04-30 The Wistar Institute Of Anatomy And Biology Canine distemper vaccines and methods of treatment using the same
RU2768749C1 (ru) * 2021-06-07 2022-03-24 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Средство специфической профилактики covid-19 для плотоядных животных
CN114480441B (zh) * 2021-12-21 2023-03-21 长春维石检测技术服务有限公司 一段核苷酸序列及其表达重组蛋白纳米颗粒在犬瘟热病毒疫苗的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US702919A (en) * 1902-02-03 1902-06-24 Adam Simpson Boyd Pipe cutter and wrench.
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
JPH04502164A (ja) 1989-10-10 1992-04-16 アムジエン・インコーポレーテツド 犬科・猫科動物における感染の治療または予防のための化学組成物及び方法
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
CA2044468C (en) 1990-11-21 2006-08-22 Richard A. Nash Canine granulocyte macrophage colony stimulating factor
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
CN1117081A (zh) * 1995-03-16 1996-02-21 高云 犬瘟热狂犬病细小病毒三联活疫苗、毒种及制造方法
WO1996034109A1 (en) 1995-04-25 1996-10-31 Vical Incorporated Single-vial formulations of dna/lipid complexes
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2750865B1 (fr) * 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
AU737243B2 (en) * 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US7294338B2 (en) 1996-07-19 2007-11-13 Merial Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
CA2745736C (en) * 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
CZ299473B6 (cs) 1997-06-30 2008-08-06 Rhone-Poulenc Rorer S. A. Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
CA2375320C (en) * 1999-06-10 2013-02-19 Merial Dna vaccines for pets or for animals used in sports
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2794648B1 (fr) * 1999-06-10 2003-03-07 Merial Sas Vaccins adn pour animaux de compagnie et de sport
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
WO2002020937A1 (en) 2000-09-06 2002-03-14 The Charles Machine Works, Inc. Auxiliary pipe loading device
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
WO2004028562A2 (de) 2002-09-23 2004-04-08 Mologen Ag Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
MXPA06000942A (es) 2003-07-24 2006-03-30 Merial Ltd Nuevas formulaciones de vacunas.
ZA200608178B (en) 2004-03-30 2008-10-29 Roussy Inst Gustave Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
WO2008036061A2 (en) * 2005-04-06 2008-03-27 Verenium Corporation Enzymes and formulations for broad-specificity decontamination of chemical and biological warfare agents
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
WO2009124309A2 (en) * 2008-04-04 2009-10-08 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same

Also Published As

Publication number Publication date
ES2676542T3 (es) 2018-07-20
US20160199483A1 (en) 2016-07-14
NZ602077A (en) 2014-08-29
JP2013521234A (ja) 2013-06-10
LT2538972T (lt) 2018-07-25
BR112012021545A2 (pt) 2018-09-04
RU2012140741A (ru) 2014-04-10
US10076566B2 (en) 2018-09-18
AU2011220410B9 (en) 2015-07-30
WO2011106743A1 (en) 2011-09-01
KR20130036209A (ko) 2013-04-11
CA2791787C (en) 2019-03-26
CA2791787A1 (en) 2011-09-01
DK2538972T3 (en) 2018-07-30
RS57759B1 (sr) 2018-12-31
CN102971010A (zh) 2013-03-13
EP2538972B1 (en) 2018-04-25
US20110236419A1 (en) 2011-09-29
AU2011220410A1 (en) 2012-09-20
HUE039735T2 (hu) 2019-01-28
SI2538972T1 (en) 2018-07-31
CY1120430T1 (el) 2019-07-10
US9327137B2 (en) 2016-05-03
RU2567337C2 (ru) 2015-11-10
HRP20181188T1 (hr) 2018-10-05
JP5898632B2 (ja) 2016-04-06
AR080313A1 (es) 2012-03-28
AU2011220410B2 (en) 2015-04-02
BR112012021545B1 (pt) 2020-11-03
ZA201206209B (en) 2013-06-26
EP2538972A1 (en) 2013-01-02
PT2538972T (pt) 2018-07-30
PL2538972T3 (pl) 2018-09-28

Similar Documents

Publication Publication Date Title
US20130197612A1 (en) Electromagnetic Radiation Therapy
Kroon et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience
Velmahos et al. Angiographic embolization of bilateral internal iliac arteries to control life-threatening hemorrhage after blunt trauma to the pelvis
US6156028A (en) Method and apparatus for therapeutic laser treatment of wounds
EP2629736B1 (en) Tissue treatment
Wood et al. Observations during hypervolemic hemodilution of patients with acute focal cerebral ischemia
US5989245A (en) Method and apparatus for therapeutic laser treatment
US20030114902A1 (en) Laser therapy for foot conditions
Pile-Spellman et al. Adenosine-induced cardiac pause for endovascular embolization of cerebral arteriovenous malformations: technical case report
US20120065552A1 (en) Macro/Micro Duty Cycle Devices, Systems, and Methods Employing Low-Frequency Ultrasound or Other Cyclical Pressure Energies
US6972028B2 (en) Method of cooling an organ
EP1599240A2 (en) A method and catheter system applicable to acute renal failure
Jost et al. Effect of normal saline bolus on cerebral blood flow in regions with low baseline flow in patients with vasospasm following subarachnoid hemorrhage
Mayer et al. Effect of 5% albumin solution on sodium balance and blood volume after subarachnoid hemorrhage
Kroon et al. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients
Park et al. Gamma knife surgery in pituitary microadenomas
Engür et al. Platelet-rich plasma for patent ductus arteriosus: an orthopaedic surgeon’s perspective
US10864321B1 (en) Joint capsule fluid delivery device
WO2011106180A1 (en) Electromagnetic radiation therapy
Pagani et al. Mitral valve reconstruction in sickle cell disease
Garner et al. Effect of triglycyl-lysine-vasopressin on skin blood flow and blood loss during wound excision in patients with burns
Kroon et al. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma
Schmidt Novel modalities to diagnose and prevent compartment syndrome
Zhao et al. Resuscitative endovascular balloon occlusion of the aorta for blood control in lumbar spine tumor resection surgery: a technical note
Dutton Fluid management for trauma; where are we now?

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION